Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.

@article{Guinney2014ModelingRP,
  title={Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.},
  author={Justin Guinney and Charles Fert{\'e} and Jonathan Dry and Robert C Mcewen and Gilles Manceau and K J Kao and Kai-Ming Chang and Claus Bendtsen and Kevin Hudson and Eric W Huang and Brian L. Dougherty and Michel P Ducreux and Jean – Charles Soria and Stephen H. Friend and Jonathan M. J. Derry and Pierre Laurent-Puig},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 1},
  pages={265-272}
}
PURPOSE KRAS wild-type status is an imperfect predictor of sensitivity to anti-EGF receptor (EGFR) monoclonal antibodies in colorectal cancer, motivating efforts to identify novel molecular aberrations driving RAS. This study aimed to build a quantitative readout of RAS pathway activity to (i) uncover molecular surrogates of RAS activity specific to colorectal cancer, (ii) improve the prediction of cetuximab response in patients, and (iii) suggest new treatment strategies. EXPERIMENTAL DESIGN… CONTINUE READING